New treatments for asthma and COPD

Thematic Poster Session
Chairs: W. Busse (Madison, United States of America), D. Singh (Manchester, United Kingdom)

Download all media

Apocynin reduces reactive oxygen species generation in airways of asthmatics J. Stefanska, A. Sarniak, A. Wlodarczyk, Z. Doniec, D. Nowak, R. Pawliczak (Rabka, Poland)
Safety, dose finding and efficacy of ectoine inhalation solution in patients with mild asthma A. Bilstein, T. Meyer, D. Probst (Witten, Gauting, Germany)
Early intervention with suplatast tosilate for prophylaxis of pediatric atopic asthma: A pilot study S. Yoshihara, M. Ono, Y. Yamada, H. Fukuda, T. Abe, O. Arisaka (Shimotsuga-gun, Japan)
Statins and outcome of COPD patients after hospitalization for COPD exacerbations K. Bartziokas, A. Papaioannou, M. Minas, A. Haniotou, K. Gourgoulianis, K. Kostikas (Larissa, Athens, Greece)
Safety, tolerability and pharmacokinetics of AZD9668, an oral neutrophil elastase inhibitor, in healthy subjects and patients with COPD K. Gunawardena, H. Gullstrand, J. Perrett (Loughborough, United Kingdom; Lund, Sweden)
Single-dose, first-in-human study of AMG 853: Pharmacokinetics, pharmacodynamics, and safety in healthy adults C. Banfield, J. Parnes, M. Emery, L. Ni, N. Zhang, P. Hodsman (Thousand Oaks, Seattle, United States Of America; Melbourne, Australia)
Multiple-dose study of AMG 853 in healthy adults: Safety and pharmacokinetics J. Parnes, C. Banfield, V. Chow, N. Zhang, P. Hodsman (Thousand Oaks, United States Of America; Melbourne, Australia)
Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy E. D. Bateman, E. R. Bleecker, W. Busse, J. Lötvall, A. Woodcock, R. Forth, H. Medley, L. Jacques, B. Haumann (Cape Town, South Africa; Winston-Salem, Madison, RTP, United States Of America; Gothenburg, Sweden; Manchester, London, United Kingdom)
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy E. R. Bleecker, E. D. Bateman, W. Busse, J. Lötvall, A. Woodcock, S. Tomkins, K. W. House, L. Jacques, B. Haumann (Winston-Salem, Madison, RTP, United States Of America; Cape Town, South Africa; Gothenberg, Sweden; Manchester, London, United Kingdom)
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy W. Busse, E. R. Bleecker, E. D. Bateman, J. Lötval, A. Woodcock, R. Forth, A. M. Davis, L. Jacques, B. Haumann (Madison, Winston-Salem, RTP, United States Of America; Cape Town, South Africa; Gothenburg, Sweden; Manchester, London, United Kingdom)
Biomarker-guided design to test clinical proof of concept in allergic respiratory diseases of UR-63325, a new H₄R antagonist R. Vives, J. Peña, J. Alfon, C. Salcedo, J. Rios, C. Pontes, M. Merlos (Palau-solità i Plegamans, Barcelona, Spain)
Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily (OD) efficacy in asthma when dosed in the evening A. Woodcock, E. R. Bleecker, E. D. Bateman, W. Busse, J. Lötvall, N. Snowise, R. Forth, L. Jacques, B. Haumann (Manchester, London, United Kingdom; Winston-Salem, Madison, RTP, United States Of America; Cape Town, South Africa; Gothenberg, Sweden)
The extent of exercise-induced oxidative stress is minimized by erdosteine, but not placebo, in severe COPD R. Dal Negro, S. Tognella, C. Micheletto, M. Visconti, S. Bertacco (Bussolengo, Italy)
Metabolism of ASM-024, a novel nicotinic agonist being developed for the treatment of asthma Y. Cormier, E. Israël-Assayag, M. C. Pepin, L. Vachon (Quebec City, Canada)
Chronotherapy with modified release prednisone improves nocturnal asthma L. Alavoine, C. Knauer, S. Witte, M. Aubier (Paris, France; Mannheim, Germany)
Bronchial thermoplasty benefits patients following withdrawal of LABA therapy R. Niven, N. Thomson, P. Corris, R. Olivenstein, H. Siersted, I. Pavord, G. Cox, D. McCromack, A. Rubin, M. Laviolette (Glasgow, Leicester, United Kingdom; Montreal, Hamilton, Ontario, Quebec, Canada; , Denmark; Porto Alegre, Brazil)
A phase I inhalation study on ASM-024, a novel nicotinic agonist being developed for the treatment of asthma L. Vachon, P. Furci, Y. Cormier (Quebec City, Canada)
Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma S. Kapoor, B. Brashier, A. Udupa, R. Pawar, R. Kodgule, S. Limaye, S. Madas, P. Pandit, B. B. Ghongane, S. Salvi (Pune, India)
A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL-5R_α monoclonal antibody, in adult asthmatics D. Gossage, G. Geba, A. Gillen, C. Le, N. Molfino (Gaithersburg, United States Of America)
Effect of oral guaifenesin (Mucinex 1200mg) on mucociliary clearance from the lungs of healthy non-smoking adults W. Bennett, A. Kala, K. Zeman, J. Wu, A. Henderson, H. Albrecht, G. Solomon (Chapel Hill, Parsippany, United States Of America)